Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Have Conflicting Sentiments on These Healthcare Companies: Imunon (IMNN) and Novo Nordisk (NVO)

Tipranks - Tipranks - Thu Apr 2, 8:34AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on Imunon (IMNN) and Novo Nordisk (NVO).

End of Quarter Sale - 50% Off TipRanks

Imunon (IMNN)

Alliance Global Partners analyst James Molloy reiterated a Buy rating on Imunon today and set a price target of $12.00. The company’s shares closed last Tuesday at $2.94.

According to TipRanks.com, Molloy ‘s ranking currently consits of 0 on a 0-5 ranking scale, with an average return of -24.8% and a 19.2% success rate. Molloy covers the Healthcare sector, focusing on stocks such as Reviva Pharmaceuticals Holdings, Neurosense Therapeutics Ltd., and Intensity Therapeutics, Inc. ;'>

Imunon has an analyst consensus of Moderate Buy, with a price target consensus of $18.50.

See the top stocks recommended by analysts >>

Novo Nordisk (NVO)

BMO Capital analyst Evan Seigerman maintained a Hold rating on Novo Nordisk yesterday and set a price target of $45.00. The company’s shares closed last Wednesday at $36.73.

According to TipRanks.com, Seigerman is a 5-star analyst with an average return of 8.3% and a 52.2% success rate. Seigerman covers the Healthcare sector, focusing on stocks such as Structure Therapeutics, Inc. Sponsored ADR, Vertex Pharmaceuticals, and Terns Pharmaceuticals. ;'>

Novo Nordisk has an analyst consensus of Hold, with a price target consensus of $43.00, representing a 17.0% upside. In a report issued on March 20, Argus Research also maintained a Hold rating on the stock.

Read More on IMNN:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).